Helsinn Therapeutics, Inc. (Helsinn)

Oncology Corporate Profile

HQ Location

1140 US Hghway 22, Suite 101
Bridgewater, NJ 8807

Company Description

The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist significantly increased lean body mass (LBM) compared with placebo in two Phase III trials comprising the largest trial program of its kind to date in non-small cell lung cancer (NSCLC) patients with cachexia, an area of significant unmet medical need.

Website: http://www.helsinn.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pracinostat (+ azacitidine)HDAC inhibitorAcute Myelogenous Leukemia (AML)IIIMEI Pharma
anaomrelinghrelin receiptor agonistAcute Myelogenous Leukemia (AML)III
anaomrelinghrelin receiptor agonistMyelodysplastic Syndrome (MDS)II

View additional information on product candidates here »

Source: http://www.helsinn.com/

Recent News Headlines

There are no news items to display